Claims
- 1. A method of therapy which results in the inhibition of erbB-2 kinase in a subject in need of such inhibition which comprises administering a therapeutically effective amount of at least one compound having one of generic formulae (I) to (V) or a pharmaceutically acceptable salt thereof:
- 2. The method of claim 1, wherein R1 is benzene, pyidone, pyrasine, pyrimidine, pyridazine, naphtalene, naphthyridine, benzofuran, benzothiophene, indole, 1H-indazole, indoline, benzopyrazole, 1,3-benzodioxole, quinazoline, pyridopyrazine, pyridopyridine, quinolone, benzothiazole, quinoxaline, benzoxazine, phtalazine or cinnoline.
- 3. The method of claim 1, wherein said inhibiton antagonizes erbB-2 cell growth signaling.
- 4. The method of claim 1, wherein said method results in the inhibition of cell proliferation and/or differentiation.
- 5. The method of claim 1, which results in the induction of apoptosis.
- 6. The method of claim 1, which results in treating cancer.
- 7. The method of claim 6, wherein said cancer is one that is characterized by cells that over-express the erbB-2 and/or the EGF receptor, cells that express a mutant ras, or cells that comprise a Bcr/Abl transfection.
- 8. The method of claim 6, wherein the cancer is selected from the group consisting of breast, colon, pancreatic, prostate, head and neck, gastric, renal, brain and CML.
- 9. The method of claim 1, wherein said compound is administered by a method selected from the group consisting of oral, intranasal, intraperitoneal, intravenous, intramuscular, intratumoral, rectal, and transdermal.
- 10. The method of claim 1, wherein the administered amount of said compound ranges from 1 mg to 1 g/kg of the weight of said subject.
- 11. The method of 10, wherein the amount of said compound more preferably ranges from 5 mg to 50 mg/kg of the weight of said subject.
- 12. The method of claim 6, which further comprises the administration of another anticancer compound, radiation, or a compound that induces apoptosis.
- 13. The method of claim 6, which further comprises the administration of herceptin.
- 14. A method of inhibiting cell growth in a subject in need of such inhibition comprising administering to a subject an effective amount of at least one compound having one of generic formulae (I) to (V) or a pharmaceutically acceptable salt thereof:
- 15. The method of claim 14, wherein said inhibition involves inhibiting erbB-2 kinase activity.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority from U.S. Provisional Patent Application Serial No. 60/221,515, filed Jul. 30, 2000, the entirety of which is incorporated herein by reference.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US01/23869 |
7/30/2001 |
WO |
|